However, our results showed that the expression of Cav‐1 was not obviously changed upon treatment of elesclomol, suggesting that Cav‐1 may not be involved in elesclomol‐induced ATP7A degradation in CRC cells (Fig. S2E). Here, CAV1 is linked to colorectal carcinoma.